Empery Asset Management’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

Empery Asset Management’s Portfolio NRSNW Stock Details NRSNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.1K	Hold	100,402	–	–	0.02%	26
2025 Q4	$36.1K	Buy	+100,402	New	+$35.7K	0.03%	23
2022 Q3	$47K	Hold	160,000	–	–	0.28%	41
2022 Q2	$82K	Hold	160,000	–	–	0.44%	22
2022 Q1	$96K	Hold	160,000	–	–	0.45%	31
2021 Q4	$15K	Buy	+160,000	New	+$143K	0.03%	68

Other funds holding NRSNW

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Empery Asset Management's NRSNW Position: Q1 2026 in Review

Empery Asset Management held its NeuroSense Therapeutics Warrant (NRSNW) position steady in Q1 2026 at 100,402 shares worth $20.1K. The position accounts for 0.02% of the portfolio, ranked #26.

Empery Asset Management first reported a position in NRSNW in Q4 2021 and has held it in 6 quarters since. The position peaked at $96K in Q1 2022. 3 funds tracked by Wall St. Rank hold NRSNW as of Q1 2026.

Empery Asset Management held 100,402 shares of NeuroSense Therapeutics Warrant worth $20.1K as of Q1 2026.
Empery Asset Management left its NeuroSense Therapeutics Warrant share count unchanged in Q1 2026.
NeuroSense Therapeutics Warrant made up 0.02% of Empery Asset Management's portfolio in Q1 2026, its #26 holding.
Empery Asset Management first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and has held it in 6 quarters since.
Empery Asset Management's NeuroSense Therapeutics Warrant position peaked at $96K in Q1 2022.
3 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q1 2026.

Based on Empery Asset Management's 13F filing for Q1 2026, filed 8 May 2026.